Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer

Front Oncol. 2018 May 22:8:167. doi: 10.3389/fonc.2018.00167. eCollection 2018.

Authors

Hung-Ming Lam¹, Eva Corey¹

Affiliation

¹ Department of Urology, University of Washington School of Medicine, Seattle, WA, United States.

No abstract available

Keywords: abiraterone; bipolar androgen therapy; castration-resistant prostate cancer; enzalutamide; supraphysiological testosterone.

Grants and funding